Buzz

Trialjectory, which is developing a new technology service to match cancer patients with clinical trials, has raised $2.7 million to finance its continued growth.

Led by Contour Venture Partners,  the new financing will be used to accelerate Trialjectory’s operations by adding more clinical trials for different cancer types and expanding the company’s outreach to caregivers, pharmaceutical companies and patients, the company said.

“As cancer is the second leading cause of death for Americans — with thousands of new cases diagnosed each year — having access to advanced treatment options is a necessity, not a privilege, as new trials provide better outcomes to patients,” said Tzvia Bader, Trialjectory chief executive and co-founder. “What’s more, one of the top obstacles that oncologists face today is the lack of clinical trial access for patients, which is due to the availability of more treatment options overall. Additionally, it is a very complex process to match the right patient with the right treatment, especially with the rise of personalized medicine.”

The company currently supports trials for breast cancer, colon cancer, bladder cancer, melanoma and myelodysplastic syndromes. Read more.